XML 61 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Research And Development
3 Months Ended
Mar. 31, 2013
Research and Development [Abstract]  
Research And Development

NOTE 4 - RESEARCH AND DEVELOPMENT (“R&D”)

 

Our research and development activites are currently carried out through our wholly-owned subsidiary, Genetic Immunity which is engaged in the development of therapeutic vaccines for several different diseases inlcuing HIV, cancer, allergies and more. Current research and development is limited to DNA sequencing as we pursue commercialization tasks related to the company’s lead product candidate therapeutic HIV vaccine DermaVir. Once Dermavir is fully commercialized we will initiate additional R&D to develop several cancer and allergy vaccines.